OPEN ACCESS Freely available online

Immunogenetics: Open Access

Short Communication

Immunoproteasome: A Specialized Arm of Cellular Immunity

Remy Josephine*

Department of Immunology, University of Warwick, Coventry, United Kingdom

DESCRIPTION

The immune system depends not only on cells and antibodies but also on highly specialized molecular machines inside cells that process proteins. One of the most important of these machines is the immunoproteasome. It is a modified form of the standard proteasome that plays a central role in immune surveillance by generating peptide fragments used for antigen presentation. Without it, the body would struggle to efficiently detect infected or abnormal cells.

To understand the immunoproteasome, it is useful to first consider the normal proteasome. In all cells, proteasomes function as protein "recycling centers," breaking down damaged, misfolded, or unneeded proteins into smaller peptides. These peptides are then reused or further processed. However, when a cell is infected by a virus or becomes cancerous, it needs a more specialized system to help alert the immune system. This is where the immunoproteasome becomes essential.

The immunoproteasome is formed when cells are exposed to inflammatory signals such as interferon-gamma. Under these conditions, certain standard proteasome subunits are replaced by immune-specific subunits, including LMP2, LMP7, and MECL-1. These changes alter the cleavage pattern of proteins, producing peptides that are better suited for presentation on Major Histocompatibility Complex Class I (MHC I) molecules.

These peptide fragments are crucial because they allow infected or abnormal cells to display "internal snapshots" of their protein content on their surface. Cytotoxic CD8+ T cells then scan these MHC I-peptide complexes. If a peptide is recognized as foreign or abnormal, the T cell can trigger the destruction of the infected or cancerous cell. In this way, the immunoproteasome plays a direct role in immune defense and immune surveillance.

One of the most important functions of the immunoproteasome is improving the efficiency of antigen processing. The peptides it generates are typically shorter and more hydrophobic at the ends, making them ideal for binding to MHC I molecules. This improves the likelihood that antigenic peptides will be successfully presented to T cells, enhancing immune recognition.

The immunoproteasome is especially active in immune-related cells such as dendritic cells, macrophages, and lymphocytes. These cells are responsible for detecting pathogens and activating immune responses. However, it can also be induced in many other cell types during infection or inflammation, allowing nearly any cell to participate in immune signaling when needed.

Beyond its role in infection control, the immunoproteasome is also involved in cancer immunology. Tumor cells often produce abnormal proteins due to mutations. The immunoproteasome helps generate tumor-specific peptides that can be recognized by T cells. This makes it an important target in cancer immunotherapy research, where boosting immune recognition of tumors is a major goal.

Interestingly, the immunoproteasome also plays a role in regulating inflammation. By influencing which peptides are generated, it can affect the types of immune responses that are activated. This makes it a key player in balancing immune activation and immune tolerance. Dysregulation of immunoproteasome activity has been linked to autoimmune diseases and chronic inflammatory conditions.

Another important aspect of the immunoproteasome is its role in maintaining protein quality control under stress conditions. During infection or cellular stress, protein damage increases significantly. The immunoproteasome helps cells cope with this increased load while simultaneously supporting immune signaling. This dual function makes it particularly important in inflammatory environments.

From a therapeutic perspective, the immunoproteasome has become a promising drug target. Selective immunoproteasome inhibitors are being studied for the treatment of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. By modulating its activity, it may be possible to reduce excessive immune responses without completely shutting down the proteasome system, which is essential for normal cellular function.

However, targeting the immunoproteasome requires careful balance. Since it plays a role in both immunity and cellular health, excessive inhibition could weaken immune defenses or disrupt normal protein turnover. Therefore, ongoing research

Correspondence to: Remy Josephine, Department of Immunology, University of Warwick, Coventry, United Kingdom, Email: josephine@gmail.com

Received: 26-Nov-2025, Manuscript No. IGOA-25-41873;**Editor assigned:** 28-Nov-2025, PreQC No. IGOA-25-41873 (PQ);**Reviewed:** 12-Dec-2025, QC No. IGOA-25-41873;**Revised:** 19-Dec-2025, Manuscript No. IGOA-25-41873 (R);**Published:** 26-Dec-2025, DOI: 10.35248/IGOA.25.10.289

Citation: Josephine R (2025). Immunoproteasome: A Specialized Arm of Cellular Immunity. Immunogenet Open Access. 10:289.

focuses on designing highly specific drugs that can fine-tune its activity rather than completely block it.

In addition, genetic variations in immunoproteasome subunits have been associated with susceptibility to certain diseases. This suggests that individual differences in antigen processing may influence how effectively the immune system responds to infections or tumors. Understanding these variations could improve personalized immunotherapy approaches in the future.

CONCLUSION

In conclusion, the Immunoproteasome is a highly specialized protein-processing system that enhances immune surveillance by generating antigenic peptides for MHC I presentation. It plays a critical role in infection control, cancer immunity, and inflammation regulation. By bridging cellular protein degradation with adaptive immune recognition, the immunoproteasome stands as a key molecular link in the body's defense system and a promising target for future medical therapies.

REFERENCES

1. Ferrington DA, Gregerson DS. Immunoproteasomes: Structure, function, and antigen presentation. Prog Mol Biol Transl Sci. 2012;109:75-112.
2. Rana PS, Ignatz-Hoover JJ, Driscoll JJ. Targeting proteasomes and the MHC Class I antigen presentation machinery to treat cancer, infections and age-related diseases. Cancers (Basel). 2023;15(23): 5632.
3. Ah Kioon MD, Pierides M, Pannellini T, Lin G, Nathan CF, Barrat FJ. Noncytotoxic inhibition of the immunoproteasome regulates human immune cells in vitro and suppresses cutaneous inflammation in the mouse. J Immunol. 2021;206(7):1631-1641.
4. Chen B, Zhu H, Yang B, Cao J. The dichotomous role of immunoproteasome in cancer: Friend or foe? Acta Pharm Sin B. 2023;13(5):1976-1989.
5. Verbrugge SE, Scheper RJ, Lems WF, de Gruijl TD, Jansen G. Proteasome inhibitors as experimental therapeutics of autoimmune diseases. Arthritis Res Ther. 2015;17(1):17.
6. Spits M, Neefjes J. Immunoproteasomes and immunotherapy a smoking gun for lung cancer? J Thorac Dis. 2016;8(7):E558-E563.
7. Joyce S. Immunoproteasomes edit tumors, which then escapes immune recognition. Eur J Immunol. 2015;45(12):3241-3245.
8. Basler M, Kirk CJ, Groettrup M. The immunoproteasome in antigen processing and other immunological functions. Int J Biochem Cell Biol. 2013;45(3):674-677.
9. Groettrup M, Kirk CJ, Basler M. Proteasomes in immune cells: more than peptide producers? Nat Rev Immunol. 2010;10(1):73-78.
10. Tanaka K. The proteasome: Overview of structure and functions. Proc Jpn Acad Ser B Phys Biol Sci. 2009;85(1):12-36.